The company's platform uses mitochondrial-based technology to identify drugs with new mechanisms of action in the field of neuroscience. By matching and validating new protein targets, the platform enables de novo drug discovery for rare pediatric epilepsies. Additionally, the company's proprietary phenotypic screening platform is uncovering new therapeutic options and potential drug targets for central nervous system diseases such as rare forms of epilepsy, autism, and aging.